New research data for trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; Enhertu®; Daiichi Sankyo) and patritumab deruxtecan (U3-1402; HER3-DXd), two DXd antibody-drug conjugates (ADC), will be presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) virtual conference to be held in San Antonio, December 8-11, 2020. 
The updated results will include data from the pivotal phase II DESTINY-Breast01 trial of trastuzumab deruxtecan, a human epidermal growth factor receptor 2 (HER2) directed ADC, reporting updated duration of response (DoR), progression-free survival (PFS), an 18-month landmark analysis of overall survival and longer-term safety seen in previously treated patients with HER2 positive metastatic breast cancer will be presented as a Spotlight Poster Discussion.
A first look at new data from the phase I/II trial of patritumab deruxtecan, a human epidermal growth factor receptor 3 (HER3) directed ADC, reporting on four expansion cohorts of patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer with varying levels of HER3 expression and triple-negative breast cancer with higher levels of HER3 expression will also be presented.
“We look forward to presenting new research data from the DESTINY-Breast01 trial, which will provide updated efficacy and duration of response results, as well as safety outcomes for trastuzumab deruxtecan of patients with previously treated HER2 positive metastatic breast cancer,” said Antoine Yver, MD, MSc, EVP, and Global Head, Oncology Research and Development, Daiichi Sankyo.
“These research data, as well as the data that will be presented for our HER3 directed ADC, patritumab deruxtecan, continue to reinforce our understanding of the activity of our DXd ADCs and the potential of our DXd ADC technology to provide a potent, durable treatment that selectively targets the cancer cells,” Yver added.
Additional data to be presented at SABCS includes the initial safety and efficacy results of a phase I trial combining trastuzumab deruxtecan with nivolumab in a cohort of patients with HER2 expressing metastatic breast cancer. Trial-in-progress updates from four additional DESTINY-Breast studies will also be presented, including a summary of the first study of trastuzumab deruxtecan in patients with early breast cancer in a head-to-head comparison with ado-trastuzumab emtansine (T-DM1; Kadcyla®; Genentech/Roche).
|Download the SABCS presentation overview|
|Trastuzumab deruxtecan (Breast cancer)|
Patritumab deruxtecan (Breast cancer)
Trastuzumab deruxtecan (Breast cancer)
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) – NCT04622319
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer – NCT04553770
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) – NCT04494425
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) – NCT04539938
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (DEBBRAH) – NCT04420598
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01) – NCT04639219
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer – NCT04294628
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07) – NCT04538742
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] – NCT03529110
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] – NCT03734029
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] – NCT03523585
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer – NCT04042701
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08) – NCT04556773
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) – NCT03742102
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) – NCT03248492
Patritumab deruxtecan (Breast cancer)
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3) – NCT04610528
Highlights of Prescribing Information
Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; Enhertu®; Daiichi Sankyo) [Prescribing Information]
Ado-trastuzumab emtansine (T-DM1; Kadcyla®; Genentech/Roche) [Prescribing Information]
 Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; Enhertu®; Daiichi Sankyo)
Featured image: The San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. Over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Courtesy: © 2015 MedMeetingImages/Todd Buchanan. Used with permission.